BofA: Investors pour into bonds, pull back from crypto
Voyager Therapeutics Inc . (NASDAQ:VYGR) stock has reached a 52-week low, touching down at the $4.00 mark, with InvestingPro data showing the stock is currently trading below its Fair Value. This latest price level reflects a significant downturn for the biotechnology company, which specializes in developing treatments for severe neurological diseases. The company maintains strong financial health with a current ratio of 8.45, indicating robust liquidity management. Over the past year, Voyager Therapeutics has seen its stock value decrease by 55.13%, indicating a challenging period for the company amidst a volatile market for biotech stocks. Despite the decline, analysts maintain optimistic targets ranging from $9 to $30 per share, and InvestingPro analysis indicates the stock is in oversold territory. Investors are closely monitoring the company’s progress on its clinical trials and strategic partnerships, which could be pivotal in determining the stock’s future trajectory. For deeper insights into VYGR’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Voyager Therapeutics announced a delay in its investigational new drug (IND) application for its ALS therapy candidate, VY9323, which was initially planned for mid-2025. This decision follows the company’s shift to explore alternative payloads due to unexpected challenges in non-human primate studies. Despite this setback, Voyager’s cash reserves are projected to support its operations until mid-2027. The company’s other gene therapy programs, including those targeting GBA1 Parkinson’s disease and Friedreich’s ataxia in collaboration with Neurocrine (NASDAQ:NBIX) Biosciences, remain on track for 2025 IND filings. Additionally, Voyager plans to submit an IND application for its tau silencing gene therapy candidate, VY1706, in 2026. Analysts at H.C. Wainwright have maintained a Buy rating with a $30 price target for Voyager, expressing optimism about its CNS-focused pipeline. Citi also initiated coverage with a Buy rating and a $12 price target, highlighting the company’s strong gene therapy pipeline and innovative delivery technology. Voyager’s ongoing development efforts and strategic collaborations continue to garner attention from the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.